Nuvation Bio Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Nuvation Bio Inc. (NUVB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $185.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $76.00K, a 12.64% decline year-over-year.
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $109.00K, a 97.04% decline year-over-year.
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $99.00K, a 53.52% decline year-over-year.
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $87.00K.
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $620.00K, a 49.01% decline from fiscal 2023.
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.22M, a 43.99% decline from fiscal 2022.
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.17M, a 44.57% decline from fiscal 2021.
- Nuvation Bio Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $3.92M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $185.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $109.00K 10-Q · filed 2026-05-04 | |||
| 2025-09-30 | $99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $186.00K derived: sum of 2 quarters · filed 2026-08-06 | $3.87M 10-Q · filed 2025-11-03 | $4.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.77M 10-Q · filed 2026-08-06 | $4.18M derived: sum of 3 quarters · filed 2026-08-06 | $4.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.69M 10-Q · filed 2026-05-04 | $4.09M derived: sum of 2 quarters · filed 2026-05-04 | $4.30M derived: sum of 3 quarters · filed 2026-05-04 | $4.30M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $407.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $620.00K derived: sum of 2 quarters · filed 2025-11-03 | $620.00K derived: sum of 3 quarters · filed 2025-11-03 | $620.00K 10-K · filed 2025-03-06 |
| 2024-09-30 | $213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $213.00K derived: sum of 2 quarters · filed 2025-11-03 | $213.00K 10-Q · filed 2025-11-03 | $213.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | $1.22M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-05-07 | $1.22M derived: sum of 3 quarters · filed 2025-05-07 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.22M derived: sum of 2 quarters · filed 2025-03-06 | $1.22M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.22M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $2.17M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.17M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $2.17M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $3.92M 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $3.92M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.92M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $3.92M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |